When does Eli Lilly report earnings?
Eli Lilly and Company · end-of-day data as of Nov 13, 2026
- ConsensusBuy · 32
- News
- Trendbullish
- MAs4 of 4
- MACD3.55
- Sector▲ +15.9%
- Earnings in82d
- P/E46.9x
- RSI70
- Support-15.1%
- Off 52w high-1.1%
- Volume0.6x
- Bollingerupper half
- FCF yield+1.4%
- 52w range$851–$1,460
- ATR+3.1%
- Off ATH-1.1%
- PT$1,403.73 -2.8%
- P/E vs own+19.1%
- P/E vs sector+45.4%
- Insiders-$14.65M
Updates with the 15-min delayed price. Not a forecast or investment advice.
![]()
The stock around its reports
Last close $1,443.50 · +76.0% over 2y · E earnings · D dividend · S split · A analyst rating change
Quarterly results
Q3 FY2026: Revenue +38.6% year over year, free cash flow 33.7% of revenue, operating margin 35.3%.
| Q3 FY2026 | Sep 30, 2026 | $24.4B | 7.22 | $8.22B | 83.9% | 35.3% | 26.4% |
| Q2 FY2026 | Jun 30, 2026 | $22.97B | 7.94 | $7.76B | 85.8% | 54.2% | 30.9% |
| Q1 FY2026 | Mar 31, 2026 | $19.8B | 8.26 | $3.01B | 81.9% | 49.4% | 37.4% |
| Q4 FY2025 | Dec 31, 2025 | $19.29B | 7.39 | $678M | 82.5% | 46.6% | 34.4% |
| Q3 FY2025 | Sep 30, 2025 | $17.6B | 6.21 | $8.61B | 82.9% | 47.6% | 31.7% |
| Q2 FY2025 | Jun 30, 2025 | $15.56B | 6.29 | $1.28B | 84.3% | 45.1% | 36.4% |
| Q1 FY2025 | Mar 31, 2025 | $12.73B | 3.06 | -$1.6B | 82.5% | 41.7% | 21.7% |
| Q4 FY2024 | Dec 31, 2024 | $13.53B | 4.88 | $727M | 82.2% | 42.0% | 32.6% |